Company Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:55:38 2024-04-25 pm EDT			5-day change	1st Jan Change
0.0112 ^USD	+6.67%		+1.82%	-49.09%

Feb. 22	Baudax Bio, Inc. Filed for Bankruptcy	CI
2023	Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

Number of employees: 9

USD in Million	2021	Weight	2022	Weight	Delta
Innovative Products for Hospital and Other Acute Care Settings 100.0 %	1	100.0 %	1	100.0 %	+17.50%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	1	100.0 %	1	100.0 %	+17.50%

Managers	Title	Age	Since
Gerri Henwood CEO	Chief Executive Officer	71	18-12-31
Natalie McAndrew DFI	Director of Finance/CFO	50	23-10-08
Diane Myers PRN	Corporate Officer/Principal	60	19-10-31

Members of the board	Title	Age	Since
Winston Churchill BRD	Director/Board Member	83	19-11-20
Gerri Henwood CEO	Chief Executive Officer	71	18-12-31
Wayne Weisman CHM	Chairman	68	19-11-20
Andrew Drechsler BRD	Director/Board Member	52	20-08-19
William Ashton BRD	Director/Board Member	73	19-11-20
Arnold Baskies BRD	Director/Board Member	74	20-08-19
Yong-Chan Kim BRD	Director/Board Member	50	23-07-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	43,593,082	43,585,476 ( 99.98 %)	0	99.98 %
Stock B	0	36,267	0	0

Name	Equities	%	Valuation
Armistice Capital LLC 2.105 %	917,734	2.105 %	11 931 $
Sabby Management LLC 2.105 %	917,734	2.105 %	11 931 $
Black Horse Capital Management LLC 1.147 %	500,000	1.147 %	6 500 $
Gerri Henwood 0.004384 %	1,911	0.004384 %	25 $
Winston Churchill 0.002682 %	1,169	0.002682 %	15 $
Wayne Weisman 0.002457 %	1,071	0.002457 %	14 $
William Ashton 0.002436 %	1,062	0.002436 %	14 $
Arnold Baskies 0.002402 %	1,047	0.002402 %	14 $
Andrew Drechsler 0.002386 %	1,040	0.002386 %	14 $
SCP Vitalife Partners 0.001897 %	827	0.001897 %	11 $

Name	Equities	%	Valuation
Yong-Chan Kim 16.69 %	4,520	16.69 %	59 $

Baudax Bio, Inc.

490 Lapp Road

19355, Malvern

http://www.baudaxbio.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BAUDAX BIO, INC.	-49.09%	551K
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research